Empgliflozin cardioprotective effect

Clinical trials for Empgliflozin cardioprotective effect explained in plain language.

Never miss a new study

Get alerted when new Empgliflozin cardioprotective effect trials appear

Sign up with your email to follow new studies for Empgliflozin cardioprotective effect, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Two diabetes drugs face off to shield hearts during breast cancer chemo

Prevention Not yet recruiting

Doxorubicin is a common chemotherapy for breast cancer, but it can damage the heart. This trial compares two diabetes drugs, empagliflozin and metformin, to see if either can protect heart function in women receiving doxorubicin-based treatment. About 150 women with breast cancer…

Matched conditions: EMPGLIFLOZIN CARDIOPROTECTIVE EFFECT

Phase 3 • Sponsor: Tanta University • Aim: Prevention

Last updated Sep 13, 2026 00:00 UTC

Empgliflozin cardioprotective effect

Get alerted when new Empgliflozin cardioprotective effect trials appear

Two diabetes drugs face off to shield hearts during breast cancer chemo